Search results for: giant cell arteritis

Giant Cell Arteritis Challenging to Diagnose, Manage

Sebastian Unizony, MD, and John H. Stone, MD, MPH | March 1, 2015

Common form of primary vasculitis difficult to identify, treat, but latest research suggests potential new therapeutic targets

Diagnose, Manage and Treat Giant Cell Arteritis

Gretchen Henkel | July 1, 2014

A rheumatologist at the California Rheumatology Alliance 10th Annual Medical & Scientific Meeting in San Francisco shares research findings on this inflammatory blood vessel disease

Letters: More on the History of Polymyalgia Rheumatica and Giant Cell Arteritis

Charles Plotz, MD, and William P. Docken, MD | May 1, 2013

These syndromes were completely ignored in U.S. literature for years

Two Inflammatory Conditions—Polymyalgia Rheumatica and Giant Cell Arteritis—Share Clinical Connection

William P. Docken MD | March 1, 2013

Polymyalgia rheumatica (PMR) and giant cell arteritis (GCA) have common clinical and epidemiologic links, but they need not occur synchronously

Giant Cell Arteritis

Staff | March 1, 2008

Giant cell arteritis (GCA)—a type of vasculitis—is a group of diseases whose typical feature is inflammation of blood vessels. The blood vessels most commonly involved are the arteries of the scalp and head (especially the arteries over the temples), which is why another term for GCA is “temporal arteritis.” GCA can overlap with another rheumatic disease called polymyalgia rheumatica, and symptoms of the two conditions can occur at the same time or separately. The causes of GCA and polymyalgia rheumatica are unknown.

Higher Fracture Risk in Patients with Polymyalgia Rheumatica, Giant-Cell Arteritis

Will Boggs MD | January 24, 2018

NEW YORK (Reuters Health)—Patients with polymyalgia rheumatica (PMR) and giant-cell arteritis (GCA) have similarly increased risks of fracture, compared with the general population, researchers have found. “It is of surprise that patients with GCA have a similar fracture risk to those with PMR,” Dr. Zoe Paskins from Keele University, in Staffordshire, told Reuters Health by…

New Analysis Reveals More Potential Contributors to Takayasu Arteritis

Bryn Nelson, PhD | June 8, 2025

Recent research led to development of a cumulative genetic risk score for Takayasu arteritis, identifying differing susceptibility between groups with different genetic ancestries.

Medium-sized blood vessels are seen in the dermis and at the dermal-subcutaneous junction. The black arrow identifies a venule, and the blue arrow points to a fibrin deposition in the vessel wall. Extravasated neutrophils and erythrocytes are seen in the interstitium.

Case Report: A Polyarteritis Nodosa Conundrum

Hannah Krebsbach, MD, Ileannette Robledo Vega, MD, Nirupa Patel, MD, & Nkechinyere Emejuaiwe, MD, MPH | March 14, 2022

Polyarteritis nodosa (PAN) is a systemic necrotizing vasculitis that typically affects medium-sized muscular arteries. The clinical subsets of PAN are idiopathic, generalized, secondary hepatitis B virus (HBV) associated and cutaneous PAN. These clinical subsets are important because of their therapeutic implications. Virtually any organ system can be affected in generalized PAN, but this vasculitis tends…

Vasculitis Guidelines in Focus, Part 5: Takayasu Arteritis

Michael Putman, MD | October 11, 2021

Andy Abril, MD, a lead author of the ACR/VF guideline for Takayasu arteritis (TAK), discusses the recommendations for TAK.

Vasculitis Guidelines in Focus, Part 4: Polyarteritis Nodosa

Michael Putman, MD | September 22, 2021

Jason Springer, MD, MS, served as one of the lead authors of the ACR/VF guidelines for polyarteritis nodosa (PAN), and talks about the recommendations specific to PAN here.